Dexcom wins FDA approval for next generation of glucose monitors for diabetes

April 6, 2018 by Mike Freeman, The San Diego Union-Tribune

San Diego's Dexcom has won regulatory approval for its latest continuous glucose monitoring system that eliminates the need for finger pricks and is nearly one-third smaller than its current wearable sensor for diabetes patients.

The Food and Drug Administration this week gave the green light to Dexcom's G6 system for delivering real time blood sugar readings. Expected to hit the U.S. market in the second quarter, the G6 targets Type 1 and insulin-taking Type 2 diabetes patients.

"We think G6 carriers are a significant improvement in performance by building on the accuracy and reliability that patients have come to expect from Dexcom continuous monitors," said Chief Executive Kevin Sayer in a conference call with analysts, "including what we believe will be a more consistent experience across all 10 days of use while eliminating the need for routine finger prick calibrations."

The approval was granted three months ahead of schedule, said Kyle Rose, an analyst with Canaccord Genuity. It also ushers in "meaningful product enhancements to help close any competitive gaps from new entrants Libre (from Abbott) and Guardian Connect (from Medtronic,)" said Rose.

Dexcom's shares gained 4.7 percent Wednesday to close at $73.28 on the Nasdaq exchange.

The G6 monitor is worn on the stomach. It contains a small sensor inserted just underneath the skin. The device wirelessly transmits glucose readings every five minutes to a smartphone, smartwatch or medical device app. It will trigger an alarm when a patient's blood sugar soars too high or drops too low.

Last fall, Abbott Labs received FDA approval for its Libre glucose monitory system for adults—challenging Dexcom's market leadership in the U.S. The Libre doesn't require finger pricks and sensors last for 10 days, compared with seven days for Dexcom's previous generation monitors, the G5, which needed finger stick calibration every day or two.

With FDA approval, Dexcom can now match Libre's features. In addition, Dexcom monitors continue to sound an alarm when patients experience blood sugar spikes or crashes—even while they're asleep.

The Libre does not automatically warn users when blood glucose reaches dangerous levels.

Dexcom declined to disclose the price for the G6 system. Insurance firms reimburse for continuous glucose monitoring for Type 1 diabetes, where high can contribute to heart disease, stroke, blindness, kidney failure and nerve damage. Low blood sugar levels can also cause dizziness, unconsciousness and, in extreme cases, death. About 1.4 million Americans are living with Type 1 diabetes, based on research estimates.

Type 2 diabetes is less dangerous but more prevalent, afflicting as many as 27 million Americans. Insurance reimburses for glucose monitors for the most advanced Type 2 patients.

The FDA's approval for Dexcom's G6 monitor allows it to be used as a stand-alone sensor or in conjunction with insulin pumps and other diabetes management devices.

"The ability of this device to work with different types of compatible devices gives patients the flexibility to tailor their diabetes management tools to best meet personal preferences," said Donald St. Pierre, an acting director at the FDA's Center for Devices and Radiological Health.

Data from the G6 can be shared with up to five people, which helps parents of diabetic children keep track of levels. And acetaminophen—the main ingredient in Tylenol—no longer interferes with the monitor's ability to deliver accurate readings.

"The G6 is a whole different platform, and we believe presents a major advancement for the continuous glucose monitoring category," said Sayer.

Baird Equity Research analyst Jeff Johnson said in a research note that less than 30 percent of Type 1 in the U.S. use continuous glucose monitors, where Dexcom is the clear technology leader in the market.

"Simply put, after focusing over the last year or two on concerns about Abbott and to a lesser extent Medtronic, we're starting to believe there are growing opportunities for Dexcom to widen its competitive advantages relative to these competitors," wrote Johnson.

Explore further: FDA OKs continuous blood sugar monitor without finger pricks (Update)


Related Stories

FDA OKs continuous blood sugar monitor without finger pricks (Update)

September 28, 2017
U.S. regulators have approved the first continuous blood sugar monitor for diabetics that doesn't need backup finger prick tests.

Fitbit, Dexcom will provide self-management tool for glucose level monitoring

September 10, 2017
(Tech Xplore)—Self-care among people with diabetes is important along with self-monitoring of blood glucose levels. Yet medical problems can trouble some people if they do not manage their diabetes aggressively enough and ...

Blood sugar monitoring system approved for children

February 4, 2014
(HealthDay)—U.S. Food and Drug Administration approval of the Dexcom G4 Platinum Continuous Monitoring System has been expanded to include children with diabetes aged 2 years to 17 years, the agency said.

New study compares two continuous glucose monitoring sensors for effectiveness and patient satisfaction

September 19, 2014
Simultaneous use of two popular continuous glucose monitoring (CGM) sensors revealed clear differences in their accuracy and in patient-rated treatment experiences, including ease of use, feelings of safety, and willingness ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

Abbott wins FDA approval for diabetes device that doesn't require routine finger pricks

October 4, 2017
Abbott Laboratories has gained clearance to start selling in the U.S. the first continuous glucose monitor that does not require people with diabetes to routinely prick their fingers.

Recommended for you

Implantable islet cells come with their own oxygen supply

April 25, 2018
Since the 1960s, researchers have been interested in the possibility of treating type 1 diabetes by transplanting islet cells—the pancreatic cells that are responsible for producing insulin when blood glucose concentration ...

Study shows drug effectiveness in reducing glucocorticoid-induced bone loss

April 25, 2018
About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect—they induce the bone loss called osteoporosis, ...

Bariatric surgery successes lead to type 2 diabetes treatment

April 24, 2018
Bariatric surgery has long yielded almost immediate health benefits for patients with type 2 diabetes, and new findings on the reasons for remission may be the key to developing drug alternatives to surgery.

Hacking human 'drug trafficking' network could make diabetes treatments more effective

April 23, 2018
Making tiny changes to existing diabetes treatments can alter how they interact with cells, and potentially make the medicines more effective.

Vitamin D deficiency linked to greater risk of diabetes

April 19, 2018
An epidemiological study conducted by researchers at University of California San Diego School of Medicine and Seoul National University suggests that persons deficient in vitamin D may be at much greater risk of developing ...

One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo

April 17, 2018
One class of drug used to treat type 2 diabetes may not reduce the risk of death when compared with placebo, suggests new findings.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.